Shannon Strom
Durham University
13 Papers
67 Citations
Shannon Strom is an academic researcher from Durham University. The author has contributed to research in topics: Metered-dose inhaler & Formoterol Fumarate. The author has an hindex of 6, co-authored 13 publications.
Chat about Author
Papers
A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
Colin Reisner,Leonardo M. Fabbri,Edward Kerwin,Charles Fogarty,Selwyn Spangenthal,Klaus F. Rabe,Gary T. Ferguson,Fernando J. Martinez,James F. Donohue,Patrick Darken,Earl St Rose,Chad Orevillo,Shannon Strom,Tracy Fischer,Michael Golden,Sarvajna Dwivedi +15 more
TL;DR: Pharmacokinetic results showed glycopyrrolate and formoterol exposure were decreased following administration via fixed-dose combination versus monocomponent MDIs; however, this was not clinically meaningful.
A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD.
Donald P. Tashkin,Fernando J. Martinez,Roberto Rodriguez-Roisin,Charles Fogarty,Mark Gotfried,Michael Denenberg,Gregory Gottschlich,James F. Donohue,Chad Orevillo,Patrick Darken,Earl St Rose,Shannon Strom,Tracy Fischer,Michael Golden,Colin Reisner +14 more
TL;DR: These findings further support selection of GP 18 μg as the optimal dose to combine with FF MDI 9.6 μg for advancement into Phase III clinical trials of GFF MDI.
21
•Journal Article
Fixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD
Colin Reisner,Earl St Rose,Shannon Strom,Tracy Fischer,Michael Golden,Mervyn Thomas,Chadwick J. Orevillo +6 more
TL;DR: Both doses of GFF-MDI were superior to PL and Tio for morning pre-dose and Peak IC assessments and these findings support the further development of G FF- MDI in patients with COPD.
15
•Journal Article
Pooled analyses of five phase 2b studies support dose selection of glycopyrrolate-formoterol (GFF) MDI (PT003) 18/9.6 μg for phase III development
Colin Reisner,Chadwick J. Orevillo,Carlos Fernandez,Patrick Darken,Earl St Rose,Michael Golden,Tracy Fischer,Shannon Strom,Christine Kollar,Klaus F. Rabe +9 more
TL;DR: Pooled analyses of FEV 1 AUC 0-12 confirm GFF MDI 18/9.6 μg is the optimal dose, and is being progressed into Phase 3, and the dose responses of GP, FF and GFFMDI have been well characterized.
9
•Journal Article
Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD
Chadwick J. Orevillo,Earl St Rose,Shannon Strom,Tracy Fischer,Michael Golden,Mervyn Thomas,Colin Reisner +6 more
TL;DR: In a randomized, double-blind, customized, unbalanced, incomplete block, crossover study conducted in patients with moderate to very severe COPD, GP-MDI 36 μg was compared to placebo (PL) and Tio (Open-label).
9